Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

Exclusion Criteria

• •1. Previous use of CDK4/6 inhibitors or PD1/PD-L1 monoclonal antibody or concurrent treatment with any other antitumor therapy;
• •2. Severe organ dysfunction;
• •3. Inability to swallow,chronic diarrhea and intestinal obstruction,there are multiple factors that affect drug intake and absorption;
• •4. Patients with known HBV or HCV infection active phase or HBV DNA≥500, or chronic phase with abnormal liver function;
• •5. History of active autoimmune disease (such as interstitial pneumonia, colitis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes)
• •6. History of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation; History of interstitial lung disease (except radiation pneumonia without hormone therapy) and non-infectious pneumonia;
• •7. History of any heart disease, including:1)medicated or clinically significant arrhythmia; 2) myocardial infarction; 3) heart failure; 4) any other cardiac disease judged by the investigator for the trial;
• •8. Patients during pregnancy and lactation, women of childbearing age who refuse to take effective contraceptive measures during the study period;
• •9. According to the discretion of the investigator, there are significant risks to patient safety or concomitant diseases affecting the patient\'s completion of the study (including but not limited to severe hypertension, severe diabetes, active infection);
• •10. Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia;
• •11. Any condition deemed inappropriate for the patient\'s participation in this study by the investigator.